Scilex Holding (SCLX) Gains from Investment Securities (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Gains from Investment Securities of $324000.0 for Q1 2026, up 5300.0% year-over-year from $6000.0 in Q1 2025, and down 98.31% on a QoQ basis from $19.2 million in Q4 2025.
Scilex Holding (SCLX) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Gains from Investment Securities for 7 consecutive years, with $324000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 5300.0% year-over-year to $324000.0; the TTM figure through Mar 2026 stood at $19.5 million (up 325600.0% YoY), while the FY2025 annual figure was $1.5 million, up 146203.5% from the prior year.
- Gains from Investment Securities came in at $324000.0 for Q1 2026 at Scilex Holding, down from $19.2 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $19.2 million in Q4 2025, with the low at -$2.5 million in Q2 2022.
- Average Gains from Investment Securities over 5 years is $1.1 million, with a median of $30000.0 recorded in 2024.
- Across the five-year window, Gains from Investment Securities slumped 3800.0% in 2022 and jumped 64160.0% in 2025, its largest moves.
- Year by year, Gains from Investment Securities stood at $685000.0 in 2022, then tumbled by 107.45% to -$51000.0 in 2023, then jumped by 41.18% to -$30000.0 in 2024, then surged by 64160.0% to $19.2 million in 2025, then slumped by 98.31% to $324000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $324000.0, $19.2 million, and $30000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 19.22 Mn |
| Dec 31, 2025 | 19.22 Mn |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Sep 30, 2024 | 476,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 121,000.00 |
| Mar 31, 2024 | 33,267.00 |
| Mar 31, 2024 | 33,267.00 |
| Dec 31, 2023 | -51,000.00 |
| Dec 31, 2023 | -51,000.00 |